Trials / Active Not Recruiting
Active Not RecruitingNCT05144841
A Study to Evaluate Zilovertamab Vedotin (MK-2140) for Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (MK-2140-004)
A Phase 2 Open-label Clinical Study to Evaluate the Efficacy and Safety of Zilovertamab Vedotin (MK-2140) in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (waveLINE-004)
- Status
- Active Not Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 140 (estimated)
- Sponsor
- Merck Sharp & Dohme LLC · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate zilovertamab vedotin with respect to objective response rate and duration of response per Lugano Response Criteria as assessed by blinded independent central review (BICR). Safety and tolerability will also be evaluated in this Phase 2, single arm, interventional study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Zilovertamab vedotin | IV infusion |
Timeline
- Start date
- 2022-01-08
- Primary completion
- 2026-04-22
- Completion
- 2026-04-22
- First posted
- 2021-12-03
- Last updated
- 2026-02-13
Locations
71 sites across 17 countries: United States, Canada, Chile, China, Czechia, Estonia, France, Greece, Israel, Italy, Norway, Poland, South Korea, Spain, Sweden, Thailand, Turkey (Türkiye)
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05144841. Inclusion in this directory is not an endorsement.